EPAS1 and neoplasm: Several approaches toward inhibition of HIF-2α have been investigated, including therapeutic ones, such as belzutifan (Welireg), a small-molecule inhibitor that suppresses binding between HIF-2α and ARNT, thus preventing necessary transcriptional activation for angiogenic and tumor proliferation (9).